Addition of immunotherapy to BCG has favorable outcomes in NMIBC

“The notable finding was that the combination was well tolerated,” says Kelly L. Stratton, MD.

In this video, Kelly L. Stratton, MD, discusses the background, findings, and takeaways of the study, “Novel weekly immunotherapy dosing with avelumab tolerated during Bacillus Calmette-Guerin induction therapy: Initial results of the ABD trial,” presented at the 2021 American Urological Association Annual Meeting.

Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.